120 related articles for article (PubMed ID: 30465366)
21. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
22. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Ramachandran A; Snehalatha C; Salini J; Vijay V
J Assoc Physicians India; 2004 Jun; 52():459-63. PubMed ID: 15645955
[TBL] [Abstract][Full Text] [Related]
23. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study.
Newton CC; Gapstur SM; Campbell PT; Jacobs EJ
Int J Cancer; 2013 May; 132(9):2186-91. PubMed ID: 23024033
[TBL] [Abstract][Full Text] [Related]
24. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
25. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
[TBL] [Abstract][Full Text] [Related]
26. Pioglitazone and oral cancer risk in patients with type 2 diabetes.
Tseng CH
Oral Oncol; 2014 Feb; 50(2):98-103. PubMed ID: 24239280
[TBL] [Abstract][Full Text] [Related]
27. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Tseng CH
J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
[TBL] [Abstract][Full Text] [Related]
28. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
[TBL] [Abstract][Full Text] [Related]
29. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.
Romero V; Peyton C; Gray I; Hemal A; Terlecki R
BMC Urol; 2014 Jan; 14():10. PubMed ID: 24461081
[TBL] [Abstract][Full Text] [Related]
30. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
31. Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Metabolism; 2014 Aug; 63(8):1049-55. PubMed ID: 24889868
[TBL] [Abstract][Full Text] [Related]
32. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
33. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Tang H; Shi W; Fu S; Wang T; Zhai S; Song Y; Han J
Cancer Med; 2018 Apr; 7(4):1070-1080. PubMed ID: 29476615
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone and bladder cancer: a propensity score matched cohort study.
Wei L; MacDonald TM; Mackenzie IS
Br J Clin Pharmacol; 2013 Jan; 75(1):254-9. PubMed ID: 22574756
[TBL] [Abstract][Full Text] [Related]
36. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
Savage S; Estacio RO; Jeffers B; Schrier RW
Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
[TBL] [Abstract][Full Text] [Related]
37. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
[TBL] [Abstract][Full Text] [Related]
38. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
39. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
